Carlos L. Arteaga, M.D., a devoted cancer researcher and clinician, was named Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in September 2017. He also serves as Associate Dean of Oncology Programs. Dr. Arteaga is internationally recognized for his work in laboratory-based translational research and advancing the care of breast cancer patients. The majority of Dr. Arteaga’s career has been as a physician-scientist in Medical Oncology at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, where he served as Associate Director for Translational/Clinical Research and Director of the Center for Cancer Targeted Therapies. At Vanderbilt, he also led a successful translational research program that includes a National Cancer Institute/National Institutes of Health SPORE award in breast cancer. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He has earned numerous accolades from the American Cancer Society, the American Association for Cancer Research (AACR), Susan G. Komen for the Cure Foundation, and the American Society of Clinical Oncology. A former President of the AACR, he serves on the boards of advisors of several cancer centers and breast cancer programs. Dr. Arteaga earned his medical degree from Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. He trained in Internal Medicine at Emory University and in Medical Oncology at the University of Texas Health Science Center at San Antonio.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
- Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL Cancer Res. 2016 Jan 76 2 440-52
- Drug response in organoids generated from frozen primary tumor tissues.
- Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC Sci Rep 2016 Jan 6 18889
- The PI3K/AKT Pathway as a Target for Cancer Treatment.
- Mayer IA, Arteaga CL Annu. Rev. Med. 2016 67 11-28
- Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
- Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ Circulation 2015 Dec 132 23 2248-58
- Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
- Young CD, Arteaga CL, Cook RS Breast Cancer Res. 2015 Dec 17 148
- HER2 missense mutations have distinct effects on oncogenic signaling and migration.
- Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH Proc. Natl. Acad. Sci. U.S.A. 2015 Nov 112 45 E6205-14
- Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy.
- Stricker T, Arteaga CL Cancer Discov 2015 Nov 5 11 1124-6
- NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
- Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM J Natl Compr Canc Netw 2015 Nov 13 11 1337-46
- In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
- Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K Nat. Genet. 2015 Oct 47 10 1212-9
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
- Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD J. Clin. Oncol. 2015 Aug 33 24 2623-31